Auxilium Pharmaceuticals PT Raised to $24.00 (AUXL)
MKM Partners upped their target price on shares of Auxilium Pharmaceuticals (NASDAQ:AUXL) from $22.00 to $24.00 in a research note issued on Monday, Analyst Ratings Net reports. The firm currently has a “buy” rating on the stock. MKM Partners’ price objective points to a potential upside of 38.01% from the stock’s previous close.
AUXL has been the subject of a number of other recent research reports. Analysts at Jefferies Group reiterated a “buy” rating on shares of Auxilium Pharmaceuticals in a research note to investors on Monday. They now have a $28.00 price target on the stock, up previously from $27.00. Separately, analysts at R. F. Lafferty downgraded shares of Auxilium Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note to investors on Monday. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Auxilium Pharmaceuticals in a research note to investors on Thursday, September 26th. They now have a $19.00 price target on the stock. Four investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $22.69.
Auxilium Pharmaceuticals (NASDAQ:AUXL) traded up 0.46% on Monday, hitting $17.39. 711,871 shares of the company’s stock traded hands. Auxilium Pharmaceuticals has a 52 week low of $13.87 and a 52 week high of $22.47. The stock’s 50-day moving average is $18.0 and its 200-day moving average is $17.07. The company has a market cap of $857.2 million and a price-to-earnings ratio of 6.63.
Auxilium Pharmaceuticals (NASDAQ:AUXL) last released its earnings data on Thursday, August 1st. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.05. The company had revenue of $100.50 million for the quarter, compared to the consensus estimate of $91.43 million. During the same quarter in the previous year, the company posted $0.16 earnings per share. The company’s revenue for the quarter was up 28.5% on a year-over-year basis. Analysts expect that Auxilium Pharmaceuticals will post $0.52 EPS for the current fiscal year.
Auxilium Pharmaceuticals, Inc is a specialty biopharmaceutical company focuses on developing and marketing products to predominantly specialist audiences.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.